BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
路透社2026/10/06 07:26October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
October 6 - ** Genmab (GMAB.CO) shares rose by about 8%, reaching a three-year high and leading the gains in the STOXX 600 Index (.STOXX)
** Genmab and AbbVie (ABBV.N) said on Monday (link) that their blood cancer drug combination therapy reduced the risk of disease progression and death in a late-stage clinical trial
** The two companies stated that, compared to the use of the R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%, with Jefferies' analysts calling these results "impressive"
** The brokerage firm added that the data "easily met the success criteria," exceeding investors' expectations by about 40%
** TD Cowen said the data established the combination therapy as a potential new standard of care, with its peak market potential exceeding $3 billion
(To assist non-English speakers, Reuters has automated the translation of this report into several other languages. As automated translation may be inaccurate or lack required context, Reuters does not guarantee the accuracy of the automated translation and provides it for reader convenience only. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BAE Systems wins Lockheed Martin contract to supply electronic warfare systems for F-35 jets
BAE Systems won a Lockheed Martin contract to supply electronic warfare systems for F-35 Lightning II fighter jets. Order covers production deliveries for F-35 Lots 20-22. Deal also includes retrofit systems to modernize older aircraft in the global F-35 fleet. BAE Systems has delivered more than 1,500 F-35 electronic warfare systems to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BAE Systems plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061000PR_NEWS_USPR_____NE64821) on October 06, 2026, and is solely responsible for the information contained therein.
Morgan Stanley: Space is the "ultimate backyard" for computing power, maintains "Overweight" rating on SpaceX (SPCX.US)
Morgan Stanley maintains an "Overweight" rating on SpaceX with a target price of $300, stating that space is the ultimate scenario for AI computing power and that the renaming to SpaceXSI reflects ambitions for superintelligence.
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
BUZZ-GEO Group shares rise after completing $650 million debt refinancing
On October 6, shares of prison operator GEO Group (GEO.N) rose 2.6% in premarket trading to $33.19. The company conducted a debt refinancing, redeeming $650 million in senior secured notes due in 2029. Its $550 million revolving credit facility maturity was extended to July 2031. Earlier this week, the company agreed to sell its ICE processing center complex in Adelanto, California for $950 million. The company also recently increased its share repurchase authorization to $1.25 billion. As of the close of the previous trading day, the company's share price had more than doubled this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Crypto prices
More
